Clinical Topics & News

Skeletal-Related Events in Patients With Multiple Myeloma and Prostate Cancer Who Receive Standard vs Extended-Interval Bisphosphonate Dosing

Author and Disclosure Information

 

References

Conclusion

In comparisons of standard- and extended-interval dosing of ZA, there was no difference in the incidence of skeletal-related events in veteran patients with bone metastases from MM or CaP.

Author disclosures
The authors report no actual or potential conflicts of interest with regard to this article.

Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.

Pages

Recommended Reading

Coordination of Care Between Primary Care and Oncology for Patients With Prostate Cancer (FULL)
Federal Practitioner
Immune Checkpoint Inhibitors for Urothelial Cancer: An Update on New Therapies (FULL)
Federal Practitioner
Prostate Cancer Surveillance After Radiation Therapy in a National Delivery System (FULL)
Federal Practitioner
Portrayal of Federal Endoscopy Technology
Federal Practitioner
Accuracy of Endoscopic Ultrasound in Staging of Early Rectal Cancer (FULL)
Federal Practitioner
Surviving Colorectal Cancer, Now at Risk for Hypertension
Federal Practitioner
Comparing Artificial Intelligence Platforms for Histopathologic Cancer Diagnosis
Federal Practitioner
New practice guideline: CRC screening isn’t necessary for low-risk patients aged 50-75 years
Federal Practitioner
KRAS-mutation colon, rectal cancers have distinct survival profiles
Federal Practitioner
Sociodemographic disadvantage confers poorer survival in young adults with CRC
Federal Practitioner